An Overview of Systematic Reviews of Danhong Injection for Ischemic Stroke

Abstract EN

Objective.

This overview is to evaluate the current evidence from systematic reviews (SRs) of Danhong injection (DHI) for ischemic stroke (IS).

Methods.

SRs of randomized controlled trials (RCTs) concerning DHI and IS were searched in six databases without language restrictions until September 2015.

Assessment of multiple systematic reviews (AMSTAR) was used to evaluate the methodological quality of all included SRs.

Result.

A total of 8 articles were included.

After the administration of DHI, clinical efficiency and neurological deficits score have marked advantages over those of the control group.

However, the overall poor quality of meta-analysis and original studies affected the reliability of the results.

Evaluation of methodological quality found that no one paper meets the requirements of all 11 items.

The main flaws of the methodology quality included the following: not providing “a priori” design and reasonable objectives, duplicate study selection not given enough attention, performing an incomprehensive literature search, not paying attention to publication bias and other bias reports, characteristics of included studies not provided in detail, and ignoring clinical heterogeneity when performing meta-analyses.

Conclusion.

The current published SRs suggest DHI appears to be a safe and effective way for IS treatment in general.

However, it lacks a high quality systematic evaluation and analysis.

The quality of SRs should be improved.

Further large sample-size and well-designed RCTs are needed.